

W claim:

1. A selective binding partner for 5-HT5 receptors, whose
5 binding affinity for 5-HT5 receptors is greater than for one
or more 5-HT receptors other than 5-HT5.
2. A binding partner as claimed in claim 1, whose binding
affinity for 5-HT5 receptors is greater than for 5-HT1D
10 and/or 5-HT1B receptors.
3. A binding partner as claimed in claim 1 or 2, which
competitively inhibits the binding of 5-CT to 5-HT5
15 receptors.
4. A binding partner as claimed in one of claims 1 to 3, wherein
the K_i values for its binding to 5-HT5 receptors is less than
 10^{-8} M, preferably less than 10^{-9} M and in particular less
than 10^{-10} M.
5. A binding partner as claimed in one of claims 1 to 4, wherein
its binding to 5-HT5 receptors stimulates GTP binding to
G proteins.
- 25 6. A binding partner as claimed in one of claims 1 to 5, wherein
its binding to 5-HT5 receptors brings about an increase in
the intracellular calcium level.
7. A binding partner as claimed in one of claims 1 to 6, wherein
30 its binding to 5-HT5 receptors brings about an induction of
phospholipase C activity.
8. A binding partner as claimed in one of claims 1 to 7, wherein
its binding to 5-HT5 receptors brings about an induction of
35 cAMP production.
9. A pharmaceutical composition comprising at least one binding
partner as claimed in one of claims 1 to 8 and a
pharmaceutically tolerable excipient and, if appropriate,
40 other active compounds.
10. The use of a binding partner for 5-HT5 receptors for
producing an agent for the treatment of cerebrovascular
disorders.

11. The use as claimed in claim 10 for the treatment of migraine, in particular for the acute treatment of migraine.
12. The use as claimed in claim 10 or 11 of a binding partner as 5 claimed in one of claims 1 to 8.
13. A process for the determination of the affinity of binding partners for 5-HT5 receptors, where the binding partner is 10 brought into contact with cell systems having 5-HT5 receptors and the binding affinity is determined.
14. A process for the determination of the activity of binding partners for 5-HT5 receptors, where the binding partner is 15 brought into contact with cell systems having 5-HT5 receptors and at least one binding partner-induced agonistic action is determined.
15. A process as claimed in claim 14, where the binding of GTP to 20 G proteins, intracellular calcium levels, the phospholipase C activity and/or the cAMP production are determined.
16. A process as claimed in either claim 14 or 15, wherein human 25 glioma cell lines or h5-HT5-transfected heterologous cell lines are used.
17. A process as claimed in claim 16, wherein h5-HT5-transfected CHO cells, h5-HT5-transfected human kidney cells, or h5-HT5-transfected C-6 glioma cells are used.
- 30 18. An in vitro screening process for the identification of a 5-HT5 receptor binding partner, where at least one process as claimed in claims 13 to 17 is used.

35

40

45